Inhaled corticosteroids in COPD
67 results
1 - 67
The effect of adding inhaled corticosteroids to tiotropium and long-acting beta 2 -agonists for chronic obstructive pulmonary disease: Cochrane systematic review- Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
- Inhaled corticosteroids versus placebo for stable chronic obstructive pulmonary disease
- Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
- Once‐daily long‐acting beta₂‐agonists/inhaled corticosteroids combined inhalers versus inhaled long‐acting muscarinic antagonists for people with chronic obstructive pulmonary disease
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
- Long‐acting muscarinic antagonist (LAMA) plus long‐acting beta‐agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease
- Inhaled corticosteroid effects on bone metabolism in asthma and mild chronic obstructive pulmonary disease: Cochrane systematic review
- Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
- Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta‐analysis
- Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review
- Oral corticosteroids for stable chronic obstructive pulmonary disease
- Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
- Long‐acting inhaled therapy (beta‐agonists, anticholinergics and steroids) for COPD: a network meta‐analysis
- Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
- Phosphodiesterase‐4 inhibitors for chronic obstructive pulmonary disease
- Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease
- Long-acting beta 2 -agonists for chronic obstructive pulmonary disease: Cochrane systematic review
- Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease
- Inhaled corticosteroids for bronchiectasis: Cochrane systematic review
- Inhaled short‐acting beta2‐agonists versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease
- Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease
- Methylxanthines for exacerbations of chronic obstructive pulmonary disease
- Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD)
- Beclometasone for chronic obstructive pulmonary disease: Cochrane systematic review
- Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease: Cochrane systematic review
- Vitamin D for the management of chronic obstructive pulmonary disease
- Oral theophylline for chronic obstructive pulmonary disease
- Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease
- Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease
- Ipratropium bromide versus short acting beta‐2 agonists for stable chronic obstructive pulmonary disease
- Tiotropium versus long‐acting beta‐agonists for stable chronic obstructive pulmonary disease
- Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults with asthma
- Prophylactic antibiotics for adults with chronic obstructive pulmonary disease: a network meta‐analysis
- Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)